Clinical Diagnostics Market in APAC - Market Analysis 2015-2019
About clinical diagnostics
Clinical diagnostics or in-vitro diagnostics is a method to perform diagnostics tests by using instruments, assay reagents, and systems to diagnose a disease or medical condition in a laboratory. Early and accurate diagnosis of life-threatening diseases such as cancer, cardiovascular disease, and influenza will boost the sales of clinical diagnostics products. Factor such as a rapid increase in the number of people with diabetes in developing countries such as in India will increase the sales of diagnostics as there are 50 million diabetes patients. Diabetes can increase the risk of active TB, and this infection can worsen the blood glucose level. To handle this types of medical cases, rapid molecular TB diagnosis is done.
Technavio's analysts forecast the clinical diagnostics market in APAC to grow at a CAGR of 12.90% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the clinical diagnostics market in APAC for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of diagnostic kits, instruments, and reagents:
Technavio Announces the Publication of its Research Report – Clinical Diagnostics Market in APAC 2015-2019
Technavio recognizes the following companies as the key players in the Clinical Diagnostics Market in APAC: Abbott, Biomerieux, Beckman Coulter Diagnostics, Roche and Qiagen
Other Prominent Vendors in the market are: Amgenix International, BD, Cepheid, DiagCor, Hologic, Life Technologies, J. Mitra & Co Pvt. Ltd, Landwind Medical, Mindray, Randox Laboratories, Span Diagnostics, Snibe Diagnostics, Sysmex, Trivitron Healthcare, Tosoh Corporation, and URIT.
Commenting on the report, an analyst from Technavio’s team said: “Genetic changes occur in all kinds of microorganisms, which make them resistant to antibiotics. Such microbes delay disease diagnosis and hinder treatment procedures. WHO reported that the number of multi-drug resistant tuberculosis cases is increasing worldwide, particularly in China and India. These countries reported a total of 220,000 cases of antibiotic-resistant infections in 2013. Early disease diagnosis helps control the rising prevalence of infectious diseases and associated costs. This has increased the demand for clinical diagnostics kits and equipment to detect multi-drug resistant or antibiotic-resistant microorganisms during diagnosis.”
According to the report, the market in APAC is developed, encouraging manufacturers to employ various strategies to increase their market shares. These strategies include new technology-based products, product line extension, and modification and upgrading of clinical diagnostic systems. Vendors also undergo M&A and invest in advertising to increase product sales and gain profits. For instance, in June 2014, Roche Diagnostics, the leading vendor in China, acquired Genia Technologies to strengthen the former's NGS product pipeline.
Further, the report states that traditional clinical diagnostic methods are time consuming, delaying results and treatment. For instance, conventional blood culturing methods can provide inaccurate results and show reduced sensitivity. Conventional PCR technology is cost-effective but time consuming. The technology lacks automation as opposed to real-time PCR, and thus takes time to provide results and delays treatment.
Abbott, Biomerieux, Beckman Coulter Diagnostics, Roche, Qiagen, Amgenix International, BD, Cepheid, DiagCor, Hologic, Life Technologies, J. Mitra & Co Pvt. Ltd, Landwind Medical, Mindray, Randox Laboratories, Span Diagnostics, Snibe Diagnostics, Sysmex, Trivitron Healthcare, Tosoh Corporation, URIT.